Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27298646 | 0.88 | SIGMAR1 (0.45) | NCF1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL18664476 | 0.86 | — | — | |
| SCHEMBL14222488 | 0.86 | — | — | |
| SCHEMBL4276632 | 0.86 | — | — | |
| SCHEMBL20552382 | 0.85 | NCF1 (0.56) | NCF1CHRM2CHRM1HRH3SIGMAR1 | |
| SCHEMBL861740 | 0.82 | — | — | |
| SCHEMBL12233405 | 0.82 | — | — | |
| SCHEMBL1010140 | 0.82 | — | — | |
| SCHEMBL24477569 | 0.80 | DRD1 (0.39) | NCF1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL4293041 | 0.80 | DRD1 (0.39) | NCF1CHRM2ADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SUZHOU HEALIRNA BIOTECHNOLOGY CO., LTD. (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4650349-A1 | COMPOUND, PREPARATION METHOD, AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITION THEREOF | Suzhou Healirna Biotechnology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20230340435-A1 | BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2017088755-A1 | AMINOPYRIMIDINE HETEROCYCLIC COMPOUND WITH ADENOSINE RECEPTOR ANTAGONISTIC ACTIVITY | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2017-06-01 | — | — | WO | disclosed |
| EP-3079728-A1 | PHOTOACOUSTIC IMAGING CONTRAST AGENT | Agency For Science, Technology And Research (SG) | 2016-10-19 | — | — | EP | disclosed |
| US-20160287727-A1 | PHOTOACOUSTIC IMAGING CONTRAST AGENT | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-10-06 | — | — | US | disclosed |
| WO-2015088444-A1 | PHOTOACOUSTIC IMAGING CONTRAST AGENT | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-18 | — | — | WO | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004072102-A2 | BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| CN-1474815-A | 4-amino-quinazolines | Ĭ��ר���ɷ�����˾ | 2004-02-11 | — | — | CN | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078099-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | SGMS1, LDLR, NR5A1 | NCF1 1304/4885CHRM2 217/4885ADRA2A 780/4885 |
| US-20230340435-A1 | BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | LDLR, PCSK9, APOB | NCF1 2774/4885CHRM2 4795/4885ADRA2A 3630/4885 |
| US-20160287727-A1 | PHOTOACOUSTIC IMAGING CONTRAST AGENT | PHOSPHO1, TAGLN2, FABP7 | NCF1 1218/4885CHRM2 2358/4885ADRA2A 1047/4885 |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | NCF1 3138/4885CHRM2 132/4885ADRA2A 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.